<DOC>
	<DOCNO>NCT00310050</DOCNO>
	<brief_summary>RATIONALE : Pemetrexed may stop growth tumor cell block enzyme need growth . Drugs use chemotherapy , gemcitabine , work different way stop growth tumor cell , either kill cell stop divide . Radiation therapy use high energy x-ray kill tumor cell . PURPOSE : This phase I trial study side effect best dose pemetrexed give together radiation therapy treat patient locally advanced pancreatic cancer .</brief_summary>
	<brief_title>Pemetrexed , Gemcitabine , Radiation Therapy Treating Patients With Locally Advanced Pancreatic Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine maximum tolerate dose pemetrexed disodium give combination upper abdominal radiotherapy induction therapy comprise gemcitabine hydrochloride pemetrexed disodium follow consolidation therapy gemcitabine hydrochloride patient locally advanced pancreatic cancer . - Determine quantitative toxicity regimen patient . Secondary - Determine quantitative qualitative dose-limiting toxicity pemetrexed disodium combination upper abdominal radiation therapy . - Evaluate pattern failure , response , survival patient 1 year OUTLINE : This open-label , nonrandomized , dose-escalation study pemetrexed disodium . - Induction therapy : Patients receive pemetrexed disodium IV 10 minute gemcitabine hydrochloride IV 30 minute day 1 . Treatment repeat every 14 day 3 course . Approximately 2 week later , patient without disease progression proceed chemoradiotherapy . - Chemoradiotherapy : Patients receive pemetrexed disodium IV 10 minute day 1 , 15 , 29 undergo radiotherapy daily 5 day week 5 ½ week . Approximately 2-3 week later , patient without disease progression proceed consolidation therapy . Cohorts 3-9 patient receive escalate dos pemetrexed disodium chemoradiotherapy maximum tolerate dose ( MTD ) determine . The MTD define dose ≤ 20 % ≤ 2 9 patient experience dose-limiting toxicity . - Consolidation therapy : Patients receive gemcitabine hydrochloride IV 30 minute day 1 8 . Treatment repeat every 21 day 2 course absence disease progression unacceptable toxicity . After completion study treatment , patient follow periodically . PROJECTED ACCRUAL : A total 25 patient accrue study .</detailed_description>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm carcinoma arise pancreas Stage II III disease , meet 1 follow criterion : Nonresectable disease Potentially resectable disease Resectable disease Stage IV disease symptomatic back pain require palliation allow discretion principal investigator Measurable , evaluable , nonmeasurable disease No neuroendocrine tumor pancreas No documented brain metastasis No clinically significant pleural peritoneal effusion drain PATIENT CHARACTERISTICS : ECOG performance status 01 Life expectancy ≥ 12 week Absolute neutrophil count ≥ 1,500/mm³ Platelet count ≥ 100,000/mm³ Hemoglobin ≥ 9 g/dL Serum bilirubin ≤ 1.5 time upper limit normal ( ULN ) Alkaline phosphatase ≤ 3 time ULN ( 5 time ULN liver tumor involvement ) AST ALT ≤ 3 time ULN ( 5 time ULN liver tumor involvement ) Creatinine clearance ≥ 45 mL/min Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 3 month completion study treatment No active infection No serious systemic disorder would preclude study treatment No significant cardiovascular disease form abnormal electrocardiogram couple clinical feature recent recurrent cardiac disease ( include myocardial infarction , angina , hypertension ) PRIOR CONCURRENT THERAPY : More 4 week since prior investigational agent No prior chemotherapy pancreatic cancer Must able discontinue aspirin , dexamethasone , nonsteroidal antiinflammatory agent 2 day , day , 2 day pemetrexed disodium dose ( 5 day longacting agent piroxicam ) Must able willing take folic acid cyanocobalamin ( vitamin B12 ) supplementation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>stage II pancreatic cancer</keyword>
	<keyword>stage III pancreatic cancer</keyword>
	<keyword>stage IV pancreatic cancer</keyword>
</DOC>